Troy Wilson

Kura Oncology leukemia clinical trial to resume after FDA lifts partial hold

The FDA placed the partial hold on the study last November following a patient death suspected to be linked to a known complication of leukemia therapies. Kura Oncology said it has reached agreement with the FDA on a mitigation strategy for that complication.

By Frank Vinluan

BioPharma, Pharma

Patient death prompts clinical trial pause for Kura Oncology leukemia drug

The FDA placed a partial clinical hold on a Kura Oncology leukemia drug following the death of one patient in the early-stage study. Kura executives said the death may be related to differentiation syndrome, a known complication of leukemia therapies.

By Frank Vinluan